Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Recurrent Pregnancy Loss

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Ain Shams University Maternity Hospital, Cairo, Cairo/القاهرة, Egypt

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

pregnant women in first trimester
negative antiphospholipid markers
normal karyotype

Exclusion criteria

multiple pregnancy
fetal malformations
maternal diseases
smoking or alcohol use
history of or risk factors for preterm labor

Treatment and study plan

Apelin-13, Apelin-36

Diagnostic Test

Serum levels of Apelin-13 and Apelin-36

Primary outcomes

Apelin-13 and Apelin-36

Time frame: 1 year

Serum levels of Apelin-13 and Apelin-36

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Evaluation of Apelin-13 and Apelin-36 Concentrations in Women With Primary Unexplained Recurrent Pregnancy Loss

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Jan 24, 2022
Registry last updated: Feb 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed